SightfileU.S. market data from official filings

Companies › URGN

UROGEN PHARMA LTD (URGN)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001668243 · EDGAR filings · Updated 2026-07-10

UROGEN PHARMA LTD (URGN) has reported institutional ownership of 95.3%, with 172 institutional managers holding positions valued at $834.8M per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Institutional ownership
95.3%
Institutional managers
172
Reported 13F value
$834.8M
Insider activity
32 trans.
−$1.08M net selling
Data flags
1 active
from SEC filings

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, UROGEN PHARMA LTD has 172 institutional holders and institutional ownership of 95.3%.

Insider activity

Insiders reported 32 transactions (0 buys, 14 sells) across 8 reporting insiders, with a net reported value of −$1.08M.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-06 (recurring since 2023-03-24) — source filing. The authoritative details are those stated in the filing itself.

Related companies

ANNEXON (ANNX) · INHIBRX BIOSCIENCES INC (INBX) · SONIDA SENIOR LIVING INC (SNDA) · JANUX THERAPEUTICS INC (JANX) · THERAVANCE BIOPHARMA INC (TBPH) · EVOMMUNE INC (EVMN)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-10.